Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

NCT06603623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

647

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: BHV-2100
DRUG: BHV-2100
DRUG: Placebo

Sponsor

Biohaven Therapeutics Ltd.